886444-14-0

Basic information

• Product Name: 2-[2-(2-fluorophenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone
• Synonyms: 2-[2-(2-fluorophenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone
• CAS NO: 886444-14-0
• Molecular Weight: 292.312
• Mol File: 886444-14-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[2-(2-fluorophenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(2-fluorophenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone(886444-14-0)
• EPA Substance Registry System: 2-[2-(2-fluorophenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone(886444-14-0)

Safety Data

• Hazardous Substances Data: 886444-14-0(Hazardous Substances Data)

Usage

Chemical Class

Pyridinyl ketones

Structure

Contains a 2-fluorophenyl group and a pyridinyl group
Kinase inhibition, particularly targeting cancer cell growth
Anti-inflammatory effects

Potential Treatments

Considered for diseases such as cancer and autoimmune disorders

Research Focus

Significant attention due to its unique structure and therapeutic potential, making it a promising candidate for future drug development.

Upstream product

• 886444-12-8 2-(2-fluorophenyl)-4-methylpyridine 
• 2524-52-9 ethyl-2-picolinate 

Relevant articles and documents

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N- (tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor

Inhibitors of transforming growth factor β (TGF-β) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.